In a first of 15 states with work compensation forms, the California Division of Workers & # 39; Compensation launched this month its process of adopting COVID-19 treatment protocols in its Injury Workers Medicine Form. has been complicated by a lack of far-reaching, evidence-based data on what works best and that most guidelines are likely to change.
"The guidelines give us a good idea of what we know today, but we must have patience and open-mindedness when new research emerges, and we can expect a revision of these guidelines as the evidence grows," said Brian Allen, Salt Lake City. -based Vice President of Government Affairs and Pharmacy Solutions for Pitch Technology Company Mitchell International Inc
On April 6, the California DWC issued a notice for a virtual public hearing on May 1
The latest ACOEM guideline contains prescription protocols for the treatment of COVID-19, for example when antiviral drugs and other treatments are recommended.
California's approach is unlikely to result in "major changes," Allen said.
"It is important to note, and it is stated by ACOEM researchers, that COVID-19 is a relatively new virus and there is still more we need to learn about how to prevent it from spreading and how to best treat it when it is contagious, he says.
"It has been a real challenge for everyone to develop evidence-based clinical guidelines because there have been so few long-term studies," said Joe Paduda, Skaneateles, New York-based principal of the Comprehensive Healthcare Associates consulting firm. LLC.
Most occupational injuries are musculoskeletal, he said. "COVID-19 is diametrically opposed to it," and the disease is developing, Paduda said.
States and compensators are usually dependent on the ACOEM or the official list of disability guidelines. developed by Austin, Texas-based MCG Health LLC to manage and update their forms.Both devices began addressing COVID-19 in the early pandemic last year.
ODG-ri The kt lines are scheduled to be updated in June, according to Dr. Laurent S. Tao, editor-in-chief of MCG Health, who oversees research to incorporate new data into guidelines – a task he said has been complicated by the nuances of COVID-19.
“It has definitely been a challenge for us as well as other organizations to offer evidence-based recommendations because there is little data; it makes it difficult for everyone to feel secure in the information we present, he said. "We are all keen to look for ongoing clinical trial results."
More insurance and work compensation news about the coronavirus crisis here .